Compare McDonald's Corp (MCD) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McDonald's Corp vs Sanofi SA — how do they compare? McDonald's Corp trades at $264 (market cap $190.16B), while Sanofi SA trades at $44.05 (market cap $104.83B). The key difference: McDonald's Corp is the larger of the two by market cap, and Sanofi SA pays the higher dividend (5.5%). Which is the better fit depends on your goals.
| MCD | SNY | |
|---|---|---|
Market Cap | $190.16B | $104.83B |
Volume | 2,230,036 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $341.06 | $52.34 |
52-Week Low | $264.54 | $41.33 |
Enterprise Value | $243.87B | $121.32B |
Dividend Yield | 2.78% | 5.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McDonald's (MCD) trades at $267.71, down 2.1% on the day, with a bearish technical signal driven by moving averages. The company reported steady revenue growth to $26.89 billion in 2025 and a net income margin of 31.62%, though Q2 2026 earnings are pending. Recent news highlights a new 'McDonald's NEXT' strategy focusing on automation and menu improvements to boost competitiveness.
The stock presents a buying opportunity with a consensus price target of $329, implying 23% upside, supported by strong analyst sentiment (58% buy ratings). Risks include inflationary pressures on franchisee margins and high long-term debt of $38.42 billion. Earnings execution and strategy rollout will be key for near-term performance.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McDonald's Corp
McDonald's Corporation franchises and operates fast-food restaurants in the global restaurant industry. The Company's restaurants serves a variety of value-priced menu products in countries around the world.
Read more on MCD →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
